TNXA and COVID-19: Current users of ACEI, ARB, statin, warfarin, direct Xa inhibitors and P2Y12 inhibitors among COVID-19 patients were all associated with lower risks of mortality, from 6% less than never users (P2Y12 inhibitors) to 20% less (direct factor Xa inhibitors) (Table 3).